Business context and reporting period
Autolus Therapeutics plc filed this audited Form 20-F for the fiscal year ended December 31, 2020; it is an annual report, not a standalone 2020 Q4 report. The company develops programmed T-cell cancer therapies and had no products approved for sale. Financial statements are prepared under U.S. GAAP and reported in U.S. dollars.
Financial performance and liquidity
| Metric (USD millions, except per-share data) | 2020 | 2019 |
|---|---|---|
| Grant income | 1.5 | 2.9 |
| License revenue | 0.2 | — |
| Research and development expense | 134.9 | 105.4 |
| General and administrative expense | 35.0 | 39.5 |
| Net loss | 142.1 | 123.8 |
| Basic and diluted loss per share | $2.76 | $2.88 |
| Net cash used in operating activities | 117.8 | 101.5 |
| Capital expenditures | 14.7 | 18.3 |
Revenue was limited to grants and licensing; there were no product sales. Gross margin is not meaningful for the company’s current pre-commercial stage. The 2020 license revenue of $0.2 million arose from a license to an investee of principal shareholder Syncona.
At December 31, 2020, cash was $153.3 million, current assets $197.0 million, and current liabilities $33.6 million. Total assets were $294.2 million and total liabilities $84.2 million. The filing reports no material financing commitments such as credit lines or guarantees; lease liabilities were $54.2 million, including $3.6 million current and $50.6 million non-current. Operating cash outflow increased year over year as development spending rose.
Management stated that cash at year-end plus $123.4 million net proceeds from January 2021 ATM sales and the February 2021 offering were expected to fund current and planned operating and capital needs for at least 12 months from the filing date. This is a forward-looking estimate, not a guarantee.
Material changes versus the prior comparable year
- Net loss widened by $18.2 million to $142.1 million. Research and development expense rose $29.5 million, principally with clinical portfolio advancement, manufacturing and process development, facilities, and personnel.
- General and administrative expense fell $4.5 million, largely because of lower non-cash share-based compensation. The prior year included a $4.1 million impairment related to discontinued Enfield facility fit-out; no comparable impairment was recorded in 2020.
- Cash used in operations increased $16.3 million. Cash declined from $210.6 million at year-end 2019 to $153.3 million at year-end 2020.
- Income tax benefit increased to $24.2 million from $15.2 million, primarily due to higher U.K. research and development tax credits.
- Cash financing proceeds were $74.4 million in 2020, compared with $108.9 million in 2019. The company issued 7.25 million ADSs in a January 2020 offering for net proceeds of $75.0 million.
Outlook, management commentary, risks and unusual items
- Pipeline and priorities: AUTO1, a CD19-targeting therapy for adult ALL, was prioritized. AUTO1’s Phase 1 ALLCAR19 data reported 16 of 19 evaluable patients with MRD-negative complete responses; the small trial also reported three cases of Grade 3 neurotoxicity and seven deaths among 20 treated patients, attributed to leukemia progression or infectious complications as detailed in the filing. Results are preliminary and do not establish efficacy or safety.
- Other programs: AUTO3 DLBCL data showed a 65% objective response rate and 51% complete response rate among 43 efficacy-evaluable patients across dose levels. In January 2021, Autolus said it would seek a partner before advancing AUTO3 further. AUTO4 interim data were expected in 2021; planned AUTO6NG and AUTO8 clinical development was also described.
- Workforce and restructuring: In January 2021, the company announced an approximately 20% headcount reduction and infrastructure changes, expecting annualized cash savings of approximately $15 million once implemented. It anticipated approximately $2.5 million of combined restructuring charges in the first half of 2021.
- Development and operating risks: The company expects continued losses and substantial spending; additional capital will be needed to develop candidates through approval. Risks include clinical failure or delays, serious adverse events, manufacturing scale-up and supply-chain execution, competition, intellectual-property disputes, regulatory uncertainty, and reimbursement and commercialization challenges.
- Other uncertainties: COVID-19 could disrupt trials, enrollment, suppliers and operations. The company has exposure to sterling-dollar currency movements and reported no currency hedging. A third-party U.S. patent issue could delay a U.S. launch of AUTO1 until relevant patents expire in 2023–2025, are invalidated, or are licensed. No material legal proceedings were reported.
Important facts for investors to verify
- Review the full clinical datasets, follow-up duration, patient denominators, adverse events and causes of death for AUTO1 and AUTO3; assess whether preliminary results persist in larger studies.
- Confirm the status, terms and timing of any AUTO3 partnership, AUTO1 registrational-trial plans, and stated 2021–2022 development milestones.
- Track cash burn, lease and manufacturing commitments, restructuring costs and realized savings against management’s stated 12-month runway estimate.
- Verify whether further equity financing is required and assess dilution, including the ATM program and post-year-end offerings.
- Assess manufacturing capacity, product-failure rates, trial enrollment, COVID-19 effects, and the regulatory and patent path for each candidate.